Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Alzheimer's Disease Genetics Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by Indiana University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT00064870
First received: July 14, 2003
Last updated: April 3, 2013
Last verified: April 2013

July 14, 2003
April 3, 2013
June 2002
June 2016   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00064870 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Alzheimer's Disease Genetics Study
Alzheimer's Disease Genetics Study

The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.

The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving DNA and data.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

blood samples

Non-Probability Sample

Families with two or more members with Alzheimer's disease or dementia

  • Alzheimer Disease
  • Late Onset Alzheimer Disease
  • Dementia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
3000
June 2016
June 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Two living family members diagnosed with AD or other dementia with any age of onset
  • Biological samples available

    • Fresh blood, or
    • Immortalized lymphoblastic cell lines, or
    • 3-5 grams of frozen cerebral cortex; fixed samples are not accepted

Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members.

Exclusion Criteria:

  • Does not meet inclusion criteria
  • Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection
Both
Not Provided
Yes
Contact: Study Coordinator 1-800-526-2839 alzstudy@iupui.edu
United States
 
NCT00064870
IA0042, U24AG021886, NIH grant U24 AG21886
No
Indiana University
Indiana University
National Institute on Aging (NIA)
Principal Investigator: Tatiana M. Foroud, PhD National Cell Repository for Alzheimer's Disease (NCRAD), Indiana University
Indiana University
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP